Capstan Medical
Developer of a catheter-based robotic delivery platform and next-generation transcatheter heart valve implants. The company focuses on minimally invasive structural heart interventions, combining robotic systems, implant design, and clinical development to expand treatment options for mitral and tricuspid valve disease. Founded in 2020 and headquartered in Santa Cruz, CA.
Industries
Nr. of Employees
medium (51-250)
Capstan Medical
Patents
Products
Catheter-based robotic delivery system
A robotic platform designed to deliver transcatheter heart valve implants with enhanced catheter stability and precise implant positioning for structural heart procedures.
Next-generation transcatheter heart valve implants
Collapsible and catheter-deliverable valve implants intended for mitral and tricuspid valve replacement or repair, developed alongside delivery platform.
Catheter-based robotic delivery system
A robotic platform designed to deliver transcatheter heart valve implants with enhanced catheter stability and precise implant positioning for structural heart procedures.
Next-generation transcatheter heart valve implants
Collapsible and catheter-deliverable valve implants intended for mitral and tricuspid valve replacement or repair, developed alongside delivery platform.
Expertise Areas
- Robotic systems engineering
- Transcatheter implant development
- Clinical imaging and procedural support
- Clinical trial planning and execution
Key Technologies
- Catheter-based robotic surgical platform
- Transcatheter heart valve implants
- Real-time embedded control (C++)
- EtherCAT fieldbus
News & Updates
Announcement of successful first-in-human cases using a robotic catheter platform to deliver mitral valve implants into human patients.
Oversubscribed $110 million Series C financing to advance clinical and development work for a robotic structural heart solution.
Series B funding round (reported at $31.4M) to accelerate development of robotics for structural heart disease.
Completed pioneering robotic-assisted transcatheter mitral valve replacement procedures in human patients.
$110M Series C round closed to fund clinical and development activities for the robotic structural heart program.
Announcement of successful first-in-human cases using a robotic catheter platform to deliver mitral valve implants into human patients.
Oversubscribed $110 million Series C financing to advance clinical and development work for a robotic structural heart solution.
Series B funding round (reported at $31.4M) to accelerate development of robotics for structural heart disease.
Completed pioneering robotic-assisted transcatheter mitral valve replacement procedures in human patients.
$110M Series C round closed to fund clinical and development activities for the robotic structural heart program.